The Role of SET Domain Containing Lysine Methyltransferase 7 in Tumorigenesis and Development

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2022 Sep 14

PMID 36101480

Authors

Shangzhen Yang

Xi Wang

Jun Bai

Baojun Duan

Affiliations

Soon will be listed here.

Abstract

SET domain containing lysine methyltransferase 7 (SETD7) belongs to the protein lysine methyltransferase family and can catalyze the monomethylation of histone H3K4, which plays a vital role in the regulation of cell cycle, cell differentiation, DNA damage response and chromatin remodeling through K/R-S/T-K (K is lysine residue) sites and the recognition of substrates mediated by SET, i-SET, and -SET domains and electrostatic action. SETD7 also can regulate the transcription of several genes including β-catenin, Cullin l and lin-28 homolog A (LIN28A), etc. In addition, the abnormal expression of SETD7 can promote the proliferation, migration, invasion of tumor cells, predict the poor prognosis of tumor patients, and may be a potential target for tumor therapy. This paper reviews the structure of SETD7, its role in tumor genesis and development, and the current research progress of relevant targeted drugs to explore its regulatory mechanism in tumor genesis and development and the prospect of targeted therapy.

Citing Articles

In silico screening of phytochemicals against chromatin modifier, SETD7 for remodeling of the immunosuppressive tumor microenvironment in renal cancer.

Gadewal N, Patidar D, Natu A, Gupta S, Bastikar V Mol Divers. 2024; .

PMID: 39602041 DOI: 10.1007/s11030-024-11038-w.

Roles of Lysine Methylation in Glucose and Lipid Metabolism: Functions, Regulatory Mechanisms, and Therapeutic Implications.

Wang Z, Liu H Biomolecules. 2024; 14(7).

PMID: 39062577 PMC: 11274642. DOI: 10.3390/biom14070862.

Methylation of the JMJD2B epigenetic regulator differentially affects its ability to coactivate the ETV1 and JUN transcription factors.

Kim T, Gu R, Janknecht R Int J Biochem Mol Biol. 2024; 14(6):101-115.

PMID: 38213775 PMC: 10776875.

References

Hou Z, Min W, Zhang R, Niu A, Li Y, Cao L . Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors. Bioorg Med Chem Lett. 2020; 30(9):127061. DOI: 10.1016/j.bmcl.2020.127061. View

Batista I, Helguero L . Biological processes and signal transduction pathways regulated by the protein methyltransferase SETD7 and their significance in cancer. Signal Transduct Target Ther. 2018; 3:19. PMC: 6043541. DOI: 10.1038/s41392-018-0017-6. View

Keating S, El-Osta A . Transcriptional regulation by the Set7 lysine methyltransferase. Epigenetics. 2013; 8(4):361-72. PMC: 3674045. DOI: 10.4161/epi.24234. View

Dhayalan A, Kudithipudi S, Rathert P, Jeltsch A . Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chem Biol. 2011; 18(1):111-20. DOI: 10.1016/j.chembiol.2010.11.014. View

Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis C, Tempst P . Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 2002; 16(4):479-89. PMC: 155346. DOI: 10.1101/gad.967202. View

Montenegro M, Sanchez-Del-Campo L, Gonzalez-Guerrero R, Martinez-Barba E, Pinero-Madrona A, Cabezas-Herrera J . Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis. Oncogene. 2016; 35(47):6143-6152. DOI: 10.1038/onc.2016.154. View

Wang T, He Y, Zhu Y, Chen M, Weng M, Yang C . Comparison of the expression and function of Lin28A and Lin28B in colon cancer. Oncotarget. 2016; 7(48):79605-79616. PMC: 5346739. DOI: 10.18632/oncotarget.12869. View

Troncone E, Monteleone G . Smad7 and Colorectal Carcinogenesis: A Double-Edged Sword. Cancers (Basel). 2019; 11(5). PMC: 6563107. DOI: 10.3390/cancers11050612. View

Zhou Y, Xia J, Xu W, Zhu X, Wu X, Hua D . Cullin-1 promotes cell proliferation in human breast cancer and is related to diabetes. Int J Biol Markers. 2016; 31(4):e375-e381. DOI: 10.5301/jbm.5000215. View

10.

Si W, Zhou J, Zhao Y, Zheng J, Cui L . SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. Cell Death Dis. 2020; 11(2):151. PMC: 7044199. DOI: 10.1038/s41419-020-2350-2. View

11.

Liu H, Li Z, Yang Q, Liu W, Wan J, Li J . Substrate docking-mediated specific and efficient lysine methylation by the SET domain-containing histone methyltransferase SETD7. J Biol Chem. 2019; 294(36):13355-13365. PMC: 6737232. DOI: 10.1074/jbc.RA119.009630. View

12.

Elkouris M, Kontaki H, Stavropoulos A, Antonoglou A, Nikolaou K, Samiotaki M . SET9-Mediated Regulation of TGF-β Signaling Links Protein Methylation to Pulmonary Fibrosis. Cell Rep. 2016; 15(12):2733-44. PMC: 4920893. DOI: 10.1016/j.celrep.2016.05.051. View

13.

Ibanez G, McBean J, Astudillo Y, Luo M . An enzyme-coupled ultrasensitive luminescence assay for protein methyltransferases. Anal Biochem. 2010; 401(2):203-10. DOI: 10.1016/j.ab.2010.03.010. View

14.

Oudhoff M, Braam M, Freeman S, Wong D, Rattray D, Wang J . SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling. Dev Cell. 2016; 37(1):47-57. DOI: 10.1016/j.devcel.2016.03.002. View

15.

Xiao B, Jing C, Wilson J, Walker P, Vasisht N, Kelly G . Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003; 421(6923):652-6. DOI: 10.1038/nature01378. View

16.

Kim S, Lee H, Han K, Kim S, Choi Y, Park S . SET7/9 methylation of the pluripotency factor LIN28A is a nucleolar localization mechanism that blocks let-7 biogenesis in human ESCs. Cell Stem Cell. 2014; 15(6):735-49. PMC: 4258232. DOI: 10.1016/j.stem.2014.10.016. View

17.

Cao L, Ren Y, Guo X, Wang L, Zhang Q, Li X . Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2/STAT3 pathway. Int J Mol Med. 2020; 45(5):1616-1626. DOI: 10.3892/ijmm.2020.4523. View

18.

Qian C, Zhou M . SET domain protein lysine methyltransferases: Structure, specificity and catalysis. Cell Mol Life Sci. 2006; 63(23):2755-63. PMC: 11136235. DOI: 10.1007/s00018-006-6274-5. View

19.

McCabe M, Ott H, Ganji G, Korenchuk S, Thompson C, Van Aller G . EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-12. DOI: 10.1038/nature11606. View

20.

Wilson J, Jing C, Walker P, Martin S, Howell S, Blackburn G . Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell. 2002; 111(1):105-15. DOI: 10.1016/s0092-8674(02)00964-9. View